NEW YORK (GenomeWeb) – Biocept said today that it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately 990,000 shares of its common stock at a price of $2.25 per share, resulting in gross proceeds of approximately $2.2 million.

Maxim Group is acting as the lead placement agent and Dawson James Securities is co-placement agent for the offering, which is expected to close on or about January 23, subject to the satisfaction of customary closing conditions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.